Amyloid beta modulators and neuroprotection in Alzheimer's disease

a critical appraisal

Chandra Sekhar Kuruva, P (Hemachandra) Reddy

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. Studies have established that Aβ-induced synaptic dysfunction is dependent on abnormal amyloid precursor protein (APP) processing caused by β- and γ-secretases, resulting in the generation of Aβ. The Aβ formed as a result of abnormal APP processing induces phosphorylated tau and activates glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Here, we review the latest research on the development of Aβ modulators for neuroprotection in AD. We also review the use of molecular inhibitors as therapeutic targets in AD.

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalDrug Discovery Today
Volume22
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Amyloid beta-Protein Precursor
Cyclin-Dependent Kinase 5
Glycogen Synthase Kinase 3
Amyloid Precursor Protein Secretases
Research
Neuroprotection
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Amyloid beta modulators and neuroprotection in Alzheimer's disease : a critical appraisal. / Kuruva, Chandra Sekhar; Reddy, P (Hemachandra).

In: Drug Discovery Today, Vol. 22, No. 2, 01.02.2017, p. 223-233.

Research output: Contribution to journalReview article

Kuruva, Chandra Sekhar ; Reddy, P (Hemachandra). / Amyloid beta modulators and neuroprotection in Alzheimer's disease : a critical appraisal. In: Drug Discovery Today. 2017 ; Vol. 22, No. 2. pp. 223-233.
@article{294659f45bb64ae8acb673309b34994f,
title = "Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal",
abstract = "Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. Studies have established that Aβ-induced synaptic dysfunction is dependent on abnormal amyloid precursor protein (APP) processing caused by β- and γ-secretases, resulting in the generation of Aβ. The Aβ formed as a result of abnormal APP processing induces phosphorylated tau and activates glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Here, we review the latest research on the development of Aβ modulators for neuroprotection in AD. We also review the use of molecular inhibitors as therapeutic targets in AD.",
author = "Kuruva, {Chandra Sekhar} and Reddy, {P (Hemachandra)}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.drudis.2016.10.010",
language = "English (US)",
volume = "22",
pages = "223--233",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Amyloid beta modulators and neuroprotection in Alzheimer's disease

T2 - a critical appraisal

AU - Kuruva, Chandra Sekhar

AU - Reddy, P (Hemachandra)

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. Studies have established that Aβ-induced synaptic dysfunction is dependent on abnormal amyloid precursor protein (APP) processing caused by β- and γ-secretases, resulting in the generation of Aβ. The Aβ formed as a result of abnormal APP processing induces phosphorylated tau and activates glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Here, we review the latest research on the development of Aβ modulators for neuroprotection in AD. We also review the use of molecular inhibitors as therapeutic targets in AD.

AB - Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. Studies have established that Aβ-induced synaptic dysfunction is dependent on abnormal amyloid precursor protein (APP) processing caused by β- and γ-secretases, resulting in the generation of Aβ. The Aβ formed as a result of abnormal APP processing induces phosphorylated tau and activates glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Here, we review the latest research on the development of Aβ modulators for neuroprotection in AD. We also review the use of molecular inhibitors as therapeutic targets in AD.

UR - http://www.scopus.com/inward/record.url?scp=85006073770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006073770&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2016.10.010

DO - 10.1016/j.drudis.2016.10.010

M3 - Review article

VL - 22

SP - 223

EP - 233

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 2

ER -